Business
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
– Approval triggers $10 million cash milestone payment to Verrica – – YCANTH® approval in Japan addresses significant unmet need of patients with molluscum – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan – WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventi
About this update from Shionogi & Co., Ltd.
[{"type":"image","alt":"Verrica Pharmaceuticals Inc.","displaySize":"","headline":null,"caption":"Verrica Pharmaceuticals Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":268,"height":117,"url":"https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/35B6rwmMy25cs4KMlGMlxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4116056db3177af00d8056bf9e9ce12b","width":268,"height":117}},"lazy":false},{"type":"text","content":"– Approval triggers $10 million cash milestone payment to Verrica –","length":67,"tagName":"p"},{"type":"text","content":"– YCANTH® approval in Japan addresses significant unmet need of patients with molluscum –","length":89,"tagName":"p"},{"type":"text","content":"– Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan –","length":114,"tagName":"p"},{"type":"text","content":"WEST CHESTER, Pa., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that its development partner, Torii Pharmaceutical Co. Ltd. (“Torii”) has received approval from the Japanese Ministry of Health, Labour and Welfare (“MHLW”) for YCANTH® (TO-208) for the treatment of Molluscum Contagiosum (“molluscum”). Torii became a wholly-owned subsidiary of Shionogi & Co., Ltd., on September 1, 2025.","length":574,"tagName":"p"},{"type":"text","content":"“We are excited to announce that our development partner, Torii, has received regulatory approval for YCANTH in Japan, enabling individuals who contract molluscum in Japan access to a safe and effective therapy,” said Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “As part of our recently amended collaboration and licensing agreement with Torii, approval of YCANTH in Japan has triggered a one-time $10 million milestone cash payment that we expect to receive in the next several weeks. This significant source of non-dilutive capital will immediately strengthen our balance sheet and help support our U.S. commercial activities as we work to establish YCANTH as the new standard of care for the treatment of molluscum.”","len...